No Data
No Data
CITIC Securities: the collagen industry's prosperity continues with significant growth among various leading companies, and there is ample potential for the future.
According to the Zhitong Finance APP, Citic Securities research report believes that the sales of restructured collagen products have been excellent, with brands such as Weweima, Kelifu, and Viyimi performing well this year.
Investors Holding Back On JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200)
It's not a stretch to say that JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) price-to-sales (or "P/S") ratio of 2.8x right now seems quite "middle-of-the-road" for companies in
Jiangsu Wuzhong Pharmaceutical Development (600200.SH) has been approved for the market for its Remdesivir Injection.
On June 12th, Gelunhui reported that Jiangsu Wuzhong (600200.SH) announced that its subsidiary, Jiangsu Wuzhong Pharmaceutical Group Co., Ltd., received the "Drug Registration Certificate" (Certificate No.: 2024S01057) issued and approved by the National Medical Products Administration for Parameve Injection (referred to as "the drug" or "this product") at its Suzhou Pharmaceutical Factory. The drug meets the relevant requirements for drug registration and has been approved for registration. Parameve is a new generation of selective inhibitor of neuraminidase, which can selectively inhibit human influenza A and B viruses.
JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Climbs 5.8% This Week, Taking Five-year Gains to 79%
JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200) shareholders might be concerned after seeing the share price drop 13% in the last month. But that doesn't change the fact that the
Jiangsu Wu Zhong (600200.SH): Net profit of 5.559 million yuan in the first quarter decreased by 82.03% year on year
Gelonghui, April 24 | Jiangsu Wuzhong (600200.SH) released its first quarter report. Operating revenue was 703 million yuan, up 14.97% year on year, and net profit was 5.059 million yuan, down 82.03% year on year. After deducting non-net loss of 1.95 million yuan, basic earnings per share were 0.007 yuan.
Subdued Growth No Barrier To JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200) With Shares Advancing 28%
Despite an already strong run, JiangSu WuZhong Pharmaceutical Development Co., Ltd. (SHSE:600200) shares have been powering on, with a gain of 28% in the last thirty days. Looking back a bit furthe
No Data